Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Morphic Holding Inc (NQ: MORF )

56.99 UNCHANGED
Last Price Updated: 4:00 PM EDT, Aug 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Morphic Holding Inc

< Previous 1 2 3 4 5 Next >
Morphic Therapeutic Announces Proposed Public Offering
From Morphic Therapeutic
Via GlobeNewswire
3 Biotech Buyout Targets to Watch
The trio all have late-stage therapies with blockbuster potential. 
Via The Motley Fool
4 Analysts Have This to Say About Morphic Holding
Via Benzinga
Xerox, Hubbell, Spotify And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Nasdaq Composite dropping around 100 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Morphic Therapeutic's Ulcerative Colitis Candidate Shows Clinically Meaningful Improvements Across Measures, Stock Soars
Via Benzinga
Morphic Holding Inc. (NASDAQ: MORF) Highlighted for Surprising Price Action
Via Investor Brand Network
Morphic Holding Inc. (NASDAQ: MORF) Leading the Way in Monday Trading Based on Percentage Gain
Via Investor Brand Network
Looking Into Morphic Holding's Return On Capital Employed
Via Benzinga
Why GE HealthCare Technologies Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Morphic Reports Positive Topline Results of the EMERALD-1 UC Main Cohort; Orally Administered MORF-057 Achieves Primary Endpoint and Demonstrates Clinically Meaningful Improvements Across Secondary and Exploratory Measures
From Morphic Therapeutic
Via GlobeNewswire
Morphic Holding: Q3 Earnings Insights
Morphic Holding (NASDAQ:MORF) reported its Q3 earnings results on Wednesday, November 2, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Morphic Announces Corporate Highlights and Financial Results for the First Quarter 2023
From Morphic Therapeutic
Via GlobeNewswire
Morphic Therapeutic to Host EMERALD-1 Topline Results Call on April 25, 2023
Call to discuss topline data from EMERALD-1 Phase 2a study of MORF-057 in adults with moderate to severe ulcerative colitis 
From Morphic Therapeutic
Via GlobeNewswire
7 Biotech Stocks to Buy for 100% Returns
If you can handle the risks associated with high volatility, these biotech stocks to buy might double the returns in your portfolio. 
Via InvestorPlace
Where Morphic Holding Stands With Analysts
Morphic Holding (NASDAQ:MORF) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Short Volatility Alert: Morphic Holding, Inc.
On Thursday, shares of Morphic Holding, Inc. (NASDAQ: MORF) experienced volatile short activity. After the activity, the stock price went up +11.64% to $31.93. The overall sentiment for MORF has been... 
Via Benzinga
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82. 
Via Benzinga
Morphic to Present at TD Cowen 43rd Annual Health Care Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at SVB Leerink Global Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Initiation of EMERALD-2 Phase 2b Clinical Trial of MORF-057 in Patients with Moderate-to-Severe Ulcerative Colitis
First patient dosed in global study of oral α4β7 integrin inhibitor 
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Participation in 2022 Jefferies London Healthcare Conference
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022
From Morphic Therapeutic
Via GlobeNewswire
Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections
Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible 
From Morphic Therapeutic
Via GlobeNewswire
Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022
From Morphic Therapeutic
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Upgrades 
Via Benzinga
Recap: Morphic Holding Q2 Earnings
  Morphic Holding (NASDAQ:MORF) reported its Q2 earnings results on Wednesday, August 3, 2022 at 08:00 AM. Here's what investors need to know about the announcement. Earnings Morphic Holding reported... 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.